Alleviate Health Raises $4.3M to Transform Clinical Trial Patient Recruitment with AI Technology
核心洞察
Alleviate Health (搜索) secured $4.3 million in seed funding led by Andreessen Horowitz (搜索) to advance its AI-powered patient recruitment platform for clinical trials.
The company has already partnered with seven of the fifteen leading site networks in the United States and managed over 500,000 patient interactions across 190+ sites.
Alleviate's human-in-the-loop AI technology operates 24/7 to verify patient eligibility and schedule visits, helping accelerate recruitment for over 300 clinical trials.
Alleviate Health (搜索) has officially launched its AI-powered patient recruitment platform alongside the completion of a $4.3 million seed funding round led by venture capital firm Andreessen Horowitz (搜索). The company's technology addresses critical inefficiencies in clinical trial patient recruitment, a persistent bottleneck that can significantly delay medical research and drug development timelines.
The startup has already established partnerships with seven of the fifteen leading site networks in the United States, including notable clients such as Alcanza (搜索), CenExel (搜索), M3 Wake (搜索), Centricity (搜索), and Eximia (搜索). These partnerships demonstrate the platform's growing adoption among major clinical research organizations.
Addressing Critical Recruitment Challenges
Clinical research sites face overwhelming operational challenges when managing thousands of potential patients for multiple trials simultaneously. Research staff must conduct extensive calls to evaluate patient eligibility, qualify candidates against strict protocol criteria, and navigate complex prescreening and scheduling processes. This labor-intensive workflow is frequently hampered by missed calls and inefficient systems, leading to trial delays and staff burnout.
"Research sites are the backbone of every clinical trial. They deserve technology built specifically for their needs and the patients they serve," said Saathvik Boompelli, CEO and Co-founder of Alleviate Health (搜索).
AI-Powered Solution with Human Oversight
Alleviate's platform leverages human-in-the-loop AI technology to automate routine recruitment tasks while maintaining essential human touchpoints. The AI agents operate around the clock, engaging potential patients through SMS and voice communication to verify eligibility against study protocols and facilitate visit scheduling.
All patient interactions, including preferences and medical information, are integrated into a clinical trial-specific customer relationship management (CRM) system designed to help research sites optimize future recruitment strategies.
"Our customers, who juggle dozens of trials at once, are now able to do more with less while delivering a truly seamless experience for patients," explained John Xu, CTO and Co-founder of Alleviate Health (搜索).
Demonstrated Impact and Scale
In its inaugural year, Alleviate Health (搜索) has managed over 500,000 patient interactions across more than 190 clinical trial sites in the United States and Canada. The platform has helped accelerate recruitment processes for over 300 distinct clinical trials, demonstrating significant operational impact across the clinical research ecosystem.
Carlos Orantes, CEO of Alcanza (搜索) Clinical Research, highlighted the platform's effectiveness: "The impact that Alleviate has had on Alcanza's recruitment function is incredible and one that I wouldn't have believed when we first got started. Alleviate has enabled the scheduling of hundreds of on-site screening appointments not just at one site but at multiple sites across the entire Alcanza network during the past 10 months of working together."
Investment and Industry Support
Beyond Andreessen Horowitz (搜索)'s lead investment, Alleviate has attracted funding from prominent industry figures including Jack Altman of Alt Capital, Ali Rowghani from First Harmonic, Sajith Wickramasekara of Benchling, Trey Holterman of Tennr, Josh Miller of Gradient Health, Max Cohen of Sprinter Health, and Christophe Rimann of Camber. This diverse investor base reflects confidence in the company's potential to transform clinical research operations.
The funding will support continued platform development and expansion as Alleviate seeks to address the growing demand for efficient patient recruitment solutions in an increasingly complex clinical trial landscape.